Towards a novel influenza vaccine: Engineering of hemagglutinin on a platform of adenovirus dodecahedron

BMC Biotechnology

Volumn 13, Issue , 2013, Pages

  Naskalska, Antonina ^a   Szolajska, Ewa ^a   Andreev, Igor ^b   Podsiadla, Malgorzata ^a   Chroboczek, Jadwiga ^a,c  

^a INSTITUTE OF BIOCHEMISTRY AND BIOPHYSICS   (Poland)

^b INSTITUTE OF MOLECULAR BIOLOGY AND GENETICS   (Ukraine)

^c LABORATOIRE TIMC IMAG   (France)

Author keywords

Adenovirus dodecahedron; Hemagglutinin; Influenza vaccine; Multivalency; Vaccine presentation platform; WW domain adaptor

Indexed keywords

ADENOVIRUS DODECAHEDRON; HEMAGGLUTININ; INFLUENZA VACCINES; MULTIVALENCY; WW-DOMAIN ADAPTOR;

AMINO ACIDS; CELL ENGINEERING; CYTOLOGY; LEAD; OLIGOMERS; PROTEINS; VIRUSES;

VACCINES;

ADENOVIRUS DODECAHEDRON; ADENOVIRUS VECTOR; BACULOVIRUS VECTOR; HEMAGGLUTININ; INFLUENZA VACCINE; PENTAMERIC PENTON BASE PROTEIN; SIGNAL PEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; CELL SURFACE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HELA CELL; HEMADSORPTION; HUMAN; HUMAN CELL; MOLECULAR CLONING; PROTEIN ASSEMBLY; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PROCESSING; VIRUS ENTRY; VIRUS LIKE AGENT;

ADENOVIRIDAE; CELLS, CULTURED; CLONING, MOLECULAR; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; HEMADSORPTION INHIBITION TESTS; HEMAGGLUTININS; INFLUENZA VACCINES; PROTEIN ENGINEERING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; SACCHAROMYCES CEREVISIAE PROTEINS; UBIQUITIN-PROTEIN LIGASE COMPLEXES; VIRAL PROTEINS;

ADENOVIRIDAE;

EID: 84878895321     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/1472-6750-13-50     Document Type: Article

References (19)

1. Kong W-P, Hood C, Yang Z-Y, Wei CJ, Xu L, Garcia-Sastre A, et al. Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccination. Proc. Natl Acad Sci USA 2006, 103:15987-15991. 10.1073/pnas.0607564103, 1613227, 17043214.
2. Powers DC, McElhaney JE, Florendo OA, Manning MC, Upshaw CM, Bentley DW, et al. Humoral and cellular immune responses following vaccination with purified recombinant hemagglutinin from influenza A (H3N2) virus. Infect Dis 1997, 175:342-351.
3. Treanor JJ, Wilkinson BE, Masseoud F, Hu-Primmer J, Battaglia R, O'Brien D, et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001, 19:1732-1737. 10.1016/S0264-410X(00)00395-9, 11166898.
4. Wang K, Holtz KM, Anderson K, Chubet R, Mahmoud W, Cox MM. Expression and purification of an influenza hemagglutinin-one step closer to a recombinant protein-based influenza vaccine. Vaccine 2006, 24:2176-2185. 10.1016/j.vaccine.2005.11.005, 16310896.
5. Cox MM, Hollister JR. FluBlok, a next generation influenza vaccine manufactured in insect cells. Biologicals 2009, 37:182-189. 10.1016/j.biologicals.2009.02.014, 19297194.
6. Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007, 25:3871-3878. 10.1016/j.vaccine.2007.01.106, 17337102.
7. Palladino G, Mozdzanowska K, Washko G, Gerhard W. Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J Virol 1995, 69:2075-2081. 188873, 7884853.
8. Knossow M, Skehel J. Variation and infectivity neutralization in influenza. J Immunol 2006, 119:1-7. Review.
9. Basha S, Hazenfeld S, Brady RC, Subbramanian RA. Comparison of antibody and T-cell responses elicited by licensed inactivated and live-attenuated influenza vaccines against H3N2 hemagglutinin. Hum Immunol 2011, 72:463-469. 10.1016/j.humimm.2011.03.001, 21414368.
10. Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 2000, 69:531-569. Review, 10.1146/annurev.biochem.69.1.531, 10966468.
11. Fender P, Ruigrok RW, Gout E, Buffet S, Chroboczek J. Adenovirus dodecahedron, a new vector for human gene transfer. J Nat Biotechnol 1997, 15:52-56.
12. Naskalska A, Szolajska E, Chaperot L, Angel J, Plumas J, Chroboczek J. Influenza recombinant vaccine: matrix protein M1 on the platform of the adenovirus dodecahedron. Vaccine 2009, 27:7385-7393. 10.1016/j.vaccine.2009.09.021, 19766576.
13. Villegas-Mendez A, Garin MI, Pineda-Molina E, Veratti E, Bueren JA, Fender P, Lenormand JL. In vivo delivery of antigens by adenovirus dodecahedron induces cellular and humoral immune responses to elicit antitumor immunity. Mol Ther 2010, 18:1046-1053. 10.1038/mt.2010.16, 2890114, 20179681.
14. Galinier R, Gout E, Lortat-Jacob H, Wood J, Chroboczek J. Adenovirus protein involved in virus internalization recruits ubiquitin-protein ligases. Biochemistry 2002, 41:14299-14305. 10.1021/bi020125b, 12450395.
15. Garcel A, Gout E, Timmins J, Chroboczek J, Fender P. Protein transduction into human cells by adenovirus dodecahedron using WW domains as universal adaptors. J Gene Med 2006, 8:524-531. 10.1002/jgm.862, 16389639.
16. Zochowska M, Paca A, Schoehn G, Andrieu JP, Chroboczek J, Dublet B, Szolajska E. Adenovirus dodecahedron, as a drug delivery vector. PLoS One 2009, 4:e5569. 10.1371/journal.pone.0005569, 2679213, 19440379.
17. Li GX, Tian ZJ, Yu H, Jin YY, Hou SH, Zhou Y, et al. Fusion of C3d with hemagglutinin enhances protective immunity against swine influenza virus. Res Vet Sci 2009, 86:406-413. 10.1016/j.rvsc.2008.09.007, 19010505.
18. Denis J, Acosta-Ramirez E, Zhao Y, Hamelin ME, Koukavica I, Baz M, et al. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 2008, 26:3395-3403. 10.1016/j.vaccine.2008.04.052, 18511159.
19. Whitacre DC, Lee BO, Milich DR. Use of hepadnavirus core proteins as vaccine platforms. Expert Rev Vaccines 2009, 8:1565-1573. Review, 10.1586/erv.09.121, 2836209, 19863249.